Go Pro
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel
NASDAQ:CPRX

Catalyst Pharmaceuticals Q2 2026 Earnings Report

Catalyst Pharmaceuticals logo
$31.47 0.00 (0.00%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$31.48 +0.02 (+0.05%)
As of 07/10/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Catalyst Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
$0.48
Beat/Miss
N/A
One Year Ago EPS
N/A

Catalyst Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$155.79 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Catalyst Pharmaceuticals Announcement Details

Quarter
Q2 2026
Date
8/5/2026
Time
After Market Closes
Conference Call Date
Thursday, August 6, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Catalyst Pharmaceuticals Earnings Headlines

Solaris Energy Infrastructure to join S&P SmallCap 600, replacing Catalyst Pharma
July 10 at 1:20 PM  |  msn.comhttps://www.msn.com/en-us/money/topstocks/solaris-energy-infrastructure-to-join-s-p-smallcap-600-replacing-catalyst-pharma/ar-AA27Cf4p
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of "Moderate Buy" by Analysts
July 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30880096
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
July 11 at 1:00 AM  |  Altimetry (Ad)
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
July 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/santhera-notes-topline-results-catalyst-050000764.html
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319637/13009/en/vamorolone-demonstrates-on-target-glucocorticoid-activity-without-the-immunosuppression-characteristic-of-traditional-corticosteroids-at-clinical-doses.html
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
June 24, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260624581199/en/catalyst-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-catalyst-pharmaceuticals-inc.---cprx/
See More Catalyst Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Catalyst Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Catalyst Pharmaceuticals and other key companies, straight to your email.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals (NASDAQ:CPRX) is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS). In addition, Catalyst markets Ruzurgi® (amifampridine) tablets for pediatric LEMS patients. Beyond these approved therapies, Catalyst is advancing its pipeline programs that aim to extend its expertise in ion channel modulators to other rare and difficult-to-treat conditions.

Founded in 2002 and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals went public on the Nasdaq Stock Market. The company focuses its operations on clinical development, regulatory strategy and commercialization activities within the United States. Catalyst continues to explore opportunities for international collaborations and licensing arrangements to broaden patient access to its rare disease portfolio.

Catalyst is led by President and Chief Executive Officer Patrick J. McEnany, who brings extensive experience in pharmaceutical product development and commercialization. Under his leadership, the company has strengthened its regulatory and commercial capabilities while advancing its pipeline toward future regulatory filings and potential approvals.

View Catalyst Pharmaceuticals Profile
Earnings Tools